Emmis Acquisition (EMIS) vs Veraxa Biotech (VRXA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Emmis Acquisition is the larger company by market cap ($162.0 million vs $155.5 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | EMIS | VRXA |
|---|---|---|
| Share price | $10.27 | $1.10 |
| Market cap | $162.02M | $155.55M |
| 1-day change | 0.00% | -8.33% |
| YTD return | +3.22% | -88.75% |
| 1-year return | — | -88.53% |
| EPS (TTM) | — | $-0.57 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $10.27 | $27.36 |
| 52-week low | $9.90 | $1.04 |
| Distance from 52-week high | 0.00% | -95.98% |
| Average volume | 13.67K | 274.75K |
| Shares outstanding | 11.94M | 141.41M |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Emmis Acquisition
EMIS stock →Emmis Acquisition Corp. focuses on effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses.
Health Care · Biotechnology: Pharmaceutical Preparations
About Veraxa Biotech
VRXA stock →VERAXA Biotech AG develops antibody-based therapeutics and antibody-drug conjugates for cancer treatment. The company develops antibody-based therapeutics, including antibody-drug conjugates and bispecific antibody formats, and offers a proprietary technology platform for functional antibody screening and bioconjugation.
Health Care · Biotechnology: Pharmaceutical Preparations
EMIS vs VRXA FAQ
Which is bigger, Emmis Acquisition or Veraxa Biotech?
Emmis Acquisition (EMIS) is larger, with a market capitalization of $162.02M compared with $155.55M for Veraxa Biotech (VRXA).
Are Emmis Acquisition and Veraxa Biotech in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.